ArticleLiver international : official journal of the International Association for the Study of the Liver2026

Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

Kazunari Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.